Xebra Brands Submits Third Product Submission to COFEPRIS, Expanding Elements Brand CBD Lineup
- None.
- None.
VANCOUVER, BC / ACCESSWIRE / April 4, 2024 / Xebra Brands Ltd. ("Xebra" or the "Company") (CSE:XBRA)(OTCQB:XBRAF)(FSE:9YC0), a leading company in the CBD and cannabis industry, is proud to announce the submission of its third product application for approval to COFEPRIS (Federal Commission for Protection Against Sanitary Risk) in Mexico for domestic production. This latest submission underscores Xebra's commitment to delivering high-quality CBD products to consumers across the country in a variety of formats.
The newest addition to Xebra's Elements brand is a topical lotion meticulously crafted to provide targeted relief and nourishment for the skin, infused with premium CBD extract. Designed with precision and care, this topical lotion offers consumers a luxurious skincare experience backed by the trusted Elements brand.
"We are thrilled to expand our Elements brand lineup with the submission of our third product for domestic production, the Elements Topical Lotion, to COFEPRIS," said Rodrigo Gallardo, Interim CEO of Xebra. "This submission represents our dedication to driving innovation and new product categories in the Mexican CBD industry, and we are confident that the Elements Topical Lotion will offer consumers a premium skincare solution unlike they have experienced before. The skin care products category represents a unique opportunity to strategically differentiate our customer base and points of distribution away from traditional consumables such as capsules and tinctures."
With the submission of the Elements Topical Lotion, Xebra now covers three major product categories in the Mexico CBD market, including topicals, tinctures, and capsules. The Company intends to continue applying for new product offerings to domestically produce products and expand into additional categories to meet the evolving needs of its consumers. Once approved by COFEPRIS, the Elements Topical Lotion will be available for purchase nationwide, providing consumers with a trusted, domestically produced solution for their skincare needs.
ABOUT XEBRA
Xebra Brands Ltd. is an international leading cannabis company dedicated to providing high-quality CBD products to consumers around the world. With a focus on compliance, quality, and innovation, Xebra is committed to leading the way in the CBD industry.
Rodrigo Gallardo
Interim CEO
For more information contact:
+1 (833) XEBRA 88
ir@xebrabrands.com
Cautionary Note Regarding Forward-Looking Information
Certain information contained in this press release constitutes forward-looking statements under applicable securities laws. Any statements that are not statements of historical fact may be deemed to be forward-looking statements, these include, without limitation, statements regarding Xebra Brands Ltd.'s expectations in respect of its ability to successfully execute its business plan or business model, the ability to obtain necessary approvals in connection with the Debt Settlement; its ability to enter into and execute partnerships or joint venture opportunities on acceptable terms; its ability to provide economic, environmental, social, or any benefits of any type in the communities it operates in or may operate it in the future; its ability to be a first mover in a country, or to obtain or retain government licenses, permits or authorizations in general, or specifically in Mexico, Canada, or elsewhere, including cannabis authorizations from the Mexican Health Regulatory Agency (COFEPRIS); its ability to satisfy the conditions of authorizations granted by COFEPRIS; its ability to successfully apply for, obtain and retain trademarks and other intellectual property in any jurisdiction; its ability to be cost competitive; its ability to commercialize, cultivate, grow, or process hemp or cannabis in Mexico, Canada, or elsewhere and related plans and timing; its ability to manufacture, commercialize or sell its CBD products,, wellness products, or other products in Mexico, Canada, or elsewhere, and its related plans and claims, including market interest and availability; its ability to create wellness products that have a therapeutic effect or benefit; plans for future growth and the direction of the business; plans to increase product volumes, the capacity of existing facilities, supplies from third party growers and contractors; expected growth of the cannabis industry generally; management's expectations, beliefs and assumptions in general, including manufacturing costs, production activity and market potential in Mexico or any jurisdiction; events or developments that Xebra expects to take place in the future; general economic conditions; and other risk factors described in the MD&A of the Company for the period ended November 30, 2023. All statements, other than statements of historical facts, are forward-looking information and statements. The words "aim", "believe", "expect", "anticipate", "contemplate", "target", "intends", "continue", "plans", "budget", "estimate", "may", "will", and similar expressions identify forward-looking information and statements. Forward-looking statements are necessarily based upon a number of estimates and assumptions that, while considered reasonable by Xebra as of the dates of such statements, are inherently subject to significant business, economic and competitive uncertainties and contingencies. Known and unknown factors could cause actual results to differ materially from those projected in the forward-looking statements. Such factors include, but are not limited to, the inability of Xebra to retain the authorizations granted by COFEPRIS, failure to receive required regulatory approvals for securities offerings, the inability to generate sufficient revenues or to raise sufficient funds to carry out its business plan; changes in government legislation, taxation, controls, regulations and political or economic developments in various countries; risks associated with agriculture and cultivation activities generally, including inclement weather, access to supply of seeds, poor crop yields, and spoilage; compliance with import and export laws of various countries; significant fluctuations in cannabis prices and transportation costs; the risk of obtaining necessary licenses and permits; inability to identify, negotiate and complete potential acquisitions, dispositions or joint ventures for any reason; the ability to retain key employees; dependence on third parties for services and supplies; non-performance by contractual counter-parties; general economic conditions; the continued growth in global demand for cannabis products and the continued increase in jurisdictions legalizing cannabis; and the timely receipt of regulatory approvals for license applications on terms satisfactory to Xebra. In addition, there is no assurance Xebra will: be a low-cost producer or exporter; obtain a dominant market position in any jurisdiction; have products that will be unique. The foregoing list is not exhaustive and Xebra undertakes no obligation to update or revise any of the foregoing except as required by law. Many of these uncertainties and contingencies could affect Xebra's actual performance and cause its actual performance to differ materially from what has been expressed or implied in any forward-looking statements made by, or on behalf of, Xebra. Readers are cautioned that forward-looking statements are not guarantees of future performance and readers should not place undue reliance on such forward-looking statements. There can be no assurance that such statements will prove to be accurate and actual results and future events could differ materially from those set out in such statements.
SOURCE: Xebra Brands Ltd
View the original press release on accesswire.com
FAQ
What is Xebra Brands 's latest product submission for approval?
What is the specialty of the Elements Topical Lotion?
How does Xebra Brands aim to differentiate its customer base?
What are the major product categories covered by Xebra in the Mexico CBD market?
Where will the Elements Topical Lotion be available once approved by COFEPRIS?
